Original Articles 272
Premature menopause or early menopause and risk of ischemic stroke Walter A. Rocca, MD, MPH, Brandon R. Grossardt, MS, Virginia M. Miller, PhD, Lynne T. Shuster, MD, and Robert D. Brown, Jr, MD, MPH The findings from seven recent observational studies challenge the consensus that estrogen is invariably a risk factor of ischemic stroke. In this study, a unifying theory is proposed, in which estrogen is protective before approximately age 50 years and may become a risk factor of ischemic stroke after age 50 years or, possibly, after age 60 years.
278
The impact of menopausal symptoms on work ability Marije Geukes, MD, Mariëlle P. van Aalst, MD, Mary C.E. Nauta, PsyD, and Henk Oosterhof, MD, PhD This cross-sectional study used the Work Ability Index and the Greene Climacteric Scale in a sample of healthy working Dutch women. The findings indicate that menopausal symptoms are negatively associated with work ability and may increase the risk of sickness absence.
283
Menopausal characteristics and physical functioning in older adulthood in the National Health and Nutrition Examination Survey III Sarah E. Tom, PhD, Rachel Cooper, PhD, Kushang V. Patel, PhD, and Jack M. Guralnik, MD, PhD In the National Health and Nutrition Examination Survey III, women with surgical menopause and earlier age at menopause had worse physical functioning in older adulthood than did women with natural menopause and later age at menopause, respectively.
290
Self-reported estrogen use and newly incident urinary incontinence among postmenopausal community-dwelling women Gina M. Northington, MD, PhD, Heather F. de Vries, MSPH, and Hillary R. Bogner, MD, MSCE Results indicate that postmenopausal community-dwelling women with a history of estrogen use for 5 years or more were more likely to report newly incident urinary incontinence with condition-specific functional loss after 10 years of follow-up.
296
Effects of yoga exercise on serum adiponectin and metabolic syndrome factors in obese postmenopausal women Jeong-Ah Lee, PhD, Jong-Won Kim, PhD, and Do-Yeon Kim, PhD The findings from this study indicate that yoga improves adiponectin levels, serum lipids, and metabolic syndrome risk factors in obese postmenopausal Korean women.
302
Progestogen levels, progesterone receptor gene polymorphisms, and mammographic density changes: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study Eunjung Lee, PhD, Sue A. Ingles, DPH, David Van Den Berg, PhD, Wei Wang, PhD, Chris LaVallee, MS, Mei-Hua Huang, PhD, Carolyn J. Crandall, MD, MS, Frank Z. Stanczyk, PhD, Gail A. Greendale, MD, and Giske Ursin, MD, PhD Data from the randomized placebo-controlled Postmenopausal Estrogen/Progestin Interventions trial showed that higher serum progestogen levels resulting from estrogen plus progestin therapy lead to greater increases in mammographic density.
311
Appendicular fat mass is positively associated with femoral neck bone mineral density in older women Elisa A. Marques, MSc, Pedro Moreira, PhD, Flávia Wanderley, MSc, Andreia N. Pizarro, MSc, José P. Leão-Rosas, MD, Jorge Mota, PhD, and Joana Carvalho, PhD Appendicular fat mass is more important than total fat mass or abdominal fat for femoral neck bone mineral density in older women. The positive association between appendicular fat mass and femoral neck BMD remained significant after adjusting for age, height, age at menopause, potential renal acid load, physical activity, and knee muscle strength.
319
Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling Begoña Pineda, PhD, Carlos Hermenegildo, PhD, Juan J. Tarín, PhD, Antonio Cano, MD, and Miguel Á ngel García-Pérez, PhD The implication of the immune system in postmenopausal bone loss raises the question of whether antiresorptive drugs acting through estrogen receptors affect immune mechanisms. This study suggests that neither raloxifene nor hormone therapy affects the immune system and that both treatments exhibit similar antiresorptive power. 
332
Effects of long-term tibolone treatment on nuclear sex steroid hormone receptors and G-proteinYcoupled estrogen receptor-1 expression in the macaque uterus Mariana Hulchiy, MD, Hua Zhang, MD, PhD, J. Mark Cline, DVM, PhD, Angelica Lindén Hirschberg, MD, PhD, and Lena Sahlin, PhD Tibolone treatment influences protein expression of sex-hormone receptors in monkey endometrium differently from that observed when using conventional hormone therapy.
339
Interaction between oral estrogen plus progestogen therapy and ABO blood groups on coagulation activation in postmenopausal women Daniela Amorim Melga0o Guimarães, PhD, Mariana Silva dos Santos, BS, Karina Braga Gomes, PhD, Johanna G. van der Bom, MD, PhD, Danyelle Romana Rios, PhD, Jarbas Cardoso, BS, Romerson Martins Franco, MD, George da Silva Teixeira, MD, Luci Maria Sant'Ana Dusse, PhD, Maria das Gra0as Carvalho, PhD, and Ana Paula Fernandes, PhD These findings suggest an interactive effect between oral estrogen plus progestogen therapy and non-O blood groups. This may contribute to the hypercoagulability state and the increased risk for venous thrombosis in women undergoing oral estrogen and progestogen therapy. 
355
Physical, psychological, and menopause-related symptoms and minor psychiatric disorders in a community-based sample of Brazilian premenopausal, perimenopausal, and postmenopausal women Karen Oppermann, MD, PhD, Sandra C. Fuchs, MD, PhD, Giovana Donato, MD, Carlos A. Bastos, MD, and Poli Mara Spritzer, MD, PhD This study identified the prevalence of physical, psychological, and menopause-related symptoms and their association with minor psychiatric disorders in a community-based sample of Brazilian premenopausal, perimenopausal, and postmenopausal women.
361
Menopause as risk factor for oxidative stress Martha A. Sánchez-Rodríguez, PhD, Mariano Zacarías-Flores, MD ObGyn, Alicia Arronte-Rosales, MSc, Elsa Correa-Muñoz, MSc, and Víctor Manuel Mendoza-Núñez, PhD Oxidative stress has been associated with numerous diseases as we age. In this study, oxidative stress is compared in premenopausal and postmenopausal women.
